Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients
· Based on the profile of C21 and emerging COVID-19 data, the ongoing Phase 3 trial has been amended to revise the primary endpoint and reduce sample size · The amendment has been adopted to reflect the current SARS-CoV-2 virus landscape and will accelerate study completion · Expected read-out during Q3 2022 Gothenburg, June 3, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces an amendment of the ongoing COVID-19 Phase 3 trial (ATTRACT-3). In